Drug-induced conditioned place preference (CPP) is linked to the addictive properties of the drug used. The number of studies that have investigated the effects of propofol on CPP is limited. Research findings suggest that nitric oxide (NO) might play an important role in substance use disorders. The present study sought to investigate the role of the nitrergic system on the rewarding effects of propofol by using the CPP protocol in rats. The experiment followed habituation, pre-conditioning, conditioning, and post conditioning sessions. Male Wistar albino rats weighing 240-290 g were divided into eight groups: control (saline), propofol (10, 20, and 40 mg/kg), the NO synthase (NOS) inhibitor NG-nitro-L-arginine methyl ester (L-NAME) alone (30 and 60 mg/kg), and in combination with propofol (30 and 60 mg/kg L-NAME plus 40 mg/kg propofol) (n = 8 for each group). The CPP effects of propofol, L-NAME, saline, and their combinations were evaluated. All the drug and saline administrations were performed by intraperitoneal (ip) injections. Propofol (10-40 mg/kg) produced CPP that was statistically significant relative to saline. Propofol-induced CPP was significantly reversed by pretreatment with L-NAME. When administered alone, L-NAME did not produce CPP and also did not produce any significant change on locomotor activity of naïve rats. Our results suggest that propofol produces CPP effects in rats and that NO-related mechanisms may be responsible for propofol-induced CPP. Thus, propofol might have the potential to be addictive, and this possibility should be considered during clinical applications of this drug.
Background and Objectives: Chronic kidney disease (CKD) is usually linked with polypharmacy and patients are invariably at risk of complex medication regimens. The present study was designed to estimate the potential drug-drug interactions (pDDIs) through the prescription patterns provided to patients of the Nephrology Transplant Unit of Cerrahpasa Medical Faculty patients. Materials and Methods: 96 patients were included in the study. pDDIs among every combination of the prescribed drug were analyzed using the Thomson Reuters Micromedex. Results: We found 149 pDDIs making 2.16 interactions per prescription with incidence rates of 69.7%. Approximately 4.1% of interactions were of significant severity, 75.1% moderate severity, and 20.8% were classified as minor pDDIs. The most frequent interactions were found between iron and aluminum, calcium or magnesium-containing products (21.37%), calcium channel blockers and beta-blockers (8.96%); and aspirin and aluminum, calcium, or magnesium-containing products (7.58%). We identified 42 drug pairs with probability of clinical significance. The most commonly reported clinical outcomes of the pDDIs were hypo- or hypertension (39.24%), decreased drug efficacy (24.05%), and arrhythmia (9.49%). Aluminum, calcium, or magnesium-containing drug products (33.10%) constituted the primary class of drugs involved in interactions. Conclusions: This study showed pharmacodynamics (49%), pharmacokinetics (42.94%) interactions, polypharmacy and gender as determinant of pDDIs. A comprehensive multicenter research is required to decrease the morbidity and ease the state burden.
1 September 2001 in Journal of Basic and Clinical Physiology and Pharmacology
Exposure of cells to oxygen concentrations higher than normal (hyperoxia) damages the molecular components of cells, resulting in cellular dysfunction and death. Metformin, a biguanide molecule used for treating non-insulin-dependent diabetes, been shown to lower blood pressure. The aim of this study was to investigate the possible effects of hyperoxia and metformin on the vascular responses of thoracic aorta to vasoactive compounds, using an in vitro rat model. In the hyperoxia-control (HC) group, the response to acetylcholine was completely abolished, but metformin treatment before (MH) or after (HM) exposure to 100% oxygen restored the response to acetylcholine to near-control values. In aortas from HC, MH, or HM groups, no significant differences were found in pD2 values to the endothelium-dependent vasodilator sodium nitroprussiate. In aortic strips from metformin-treated rats, the pD2 values for noradrenaline in the presence of endothelium were significantly smaller than those in the normal control group. The maximal contractile responses to KCl were not significantly different among all experimental groups. The results of the present study show that in hyperoxia-exposed rats, metformin treatment reverses the abolished vascular relaxation to AChe.
29 July 2025 in Psychiatry and Clinical Psychopharmacology
Background: This study aims to investigate the effects of vitamin B12 on morphine-induced conditioned place preference (CPP), a model commonly used to assess the rewarding effects of drugs. Morphine is a potent analgesic widely used for moderate to severe pain, but it also poses a significant risk of addiction. Previous studies suggest that cyanocobalamin (vitamin B12) may enhance the analgesic effects of morphine and reduce tolerance, but its impact on morphine addiction remains unclear. Methods: The experiment followed phases of habituation, pre-conditioning, conditioning, and post conditioning. Adult male Wistar albino rats (250-300 g) were randomly divided into 3 groups (n=8 per group): control (saline), morphine (10 mg/kg), and a combination group of vitamin B12 (2 mg/kg) with morphine. The effects of saline, morphine, and the morphine-vitamin B12 combination on CPP were assessed. All drugs and saline were administered intraperitoneally (ip). Results: Morphine (10 mg/kg) significantly induced CPP compared to the saline group (P < .0001). Vitamin B12 (2 mg/kg) did not produce a statistically significant difference in morphine-induced CPP compared to the control group. Conclusion: Morphine induces a significant place preference, and vitamin B12 did not produce a statistically significant difference in reducing this effect. Further research with different doses of vitamin B12 is necessary to fully investigate these effects.
30 September 2022 in Archives of Current Medical Research
Background : Rewarding properties of morphine constitue the principal reasons for drug-craving behaviors which appear during morphine addiction. Varenicline and bupropion were reported to have some positive effects on addictive substances by different studies. In this study, the effects of varenicline and bupropion on morphine rewarding properties were investigated via conditioned place preference (CPP) in rats. Methods: Conditioning was performed by intraperitoneal (i.p.) administration of morphine (10 mg/kg, i.p., 1, 3, 5, and 7 days) and saline (2,4, 6, and 8 days). To evaluate the development of dependence, subcutaneous administration of varenicline (0.5, 1 and 2 mg/kg, s.c.) or bupropion (5, 10 and 20 mg/kg, i.p.) was carried out 15 minutes before the administration of morphine. To evaluate the expression of dependence, varenicline or bupropion was administered 15 minutes before the test on 9th day. To investigate the extinction of the reward effect, drugs were tested daily on days 14, 18, and 22 and evaluated for reinstatement on 23rd day. Results: Systemic morphine administration statistically significant produced CPP. Varenicline and bupropion did not reduce the development of morphine-induced CPP. In addition, varenicline and bupropion decreased expression, reinstatement and accelerated the extinction of morphine-induced CPP. Unlike varenicline, bupropion statistically significant produced CPP and altered locomotor activity. Conclusions: These data suggest that varenicline and bupropion may be useful therapeutic pharmacological agents to reduce morphine dependence. The results of our research provide preliminary evidence to highlight the importance of the effects of varenicline and bupropion on morphine dependence. In the future, it would be appropriate to conduct mechanistic studies to explain the underlying mechanisms by using different methods on the subject.